Introduction: Immunotherapy has shown efficacy in the treatment of different malignancies. Nivolumab, an immune checkpoint inhibitor directed against programmed death-1, has been approved for non-small cell lung cancer (NSCLC) in pretreated patients. Although it is generally well-tolerated, immunotherapy may be complicated by a wide range of immune-mediated adverse events. We describe the case of an uncommon skin toxicity arising as alopecia universalis induced by nivolumab in a patient with NSCLC. Case description: A 58-year-old man received nivolumab for metastatic NSCLC after progression to 3 lines of chemotherapy. The treatment was prescribed in June 2016, and induced a rapid and significant disease response. Nivolumab was well-tolerated until May 2017, when partial alopecia at hair and eyelashes appeared. In the next months, alopecia became complete and extended to the whole body surface. The dermatologic picture was compatible with alopecia areata. A topical steroid therapy was attempted, without benefit. The patient refused systemic treatments and is still undergoing nivolumab without new toxicities and with persistent disease response. Conclusions: This case suggests that alopecia areata may be a rare immune-related adverse event of immune checkpoint agents. Its late onset in our patient is uncommon and unexpected, underlining that the risk of nivolumab-induced toxicity is not limited to the beginning of treatment. Despite its rarity, alopecia areata should be considered in the range of adverse events potentially induced by immune checkpoint inhibitors even in the long term. Potential association between toxicity and efficacy of immunotherapy in NSCLC warrants further investigation.
Introduction
Immune checkpoint inhibitors (ICIs) are a class of anticancer drugs that stimulate immune response towards neoplastic cells through different molecular mechanisms. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which binds programmed death-1 (PD-1) expressed on T lymphocytes. Hence it blocks its interaction with programmed death ligand-1 (PD-L1) physiologically present on antigen-presenting cells, but also on tumor cells. The complex PD-1/PD-L1 has an inhibitory effect on Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer T lymphocytes and is a crucial mechanism through which tumor cells escape immune surveillance. In recent years, the efficacy of nivolumab has been proved in the treatment of different malignancies, such as melanoma, lung cancer, and head and neck cancer. 1 In particular, this drug has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) in second or more advanced lines of therapy, irrespective of PD-L1 expression. 2 All ICIs can induce immune-related adverse events (AEs) potentially affecting various organs, with different grades of severity and time of insurgence. Skin toxicity is infrequent and generally limited to pruritus, erythematous rash, and less commonly vitiligo. The onset of dermatologic AEs is often early and their grade of severity is usually mild to moderate. 3 Herein we report a particularly uncommon manifestation of delayed skin toxicity, associated with an exceptional disease response, in a patient with advanced NSCLC receiving nivolumab. The patient provided written informed consent for the publication of his case.
Case description
In 2014, a 58-year-old current smoker with a smoking history of 30 pack-years was diagnosed with right lung adenocarcinoma extended to mediastinal nodes, with an isolated right cerebellar lesion determining compression of the fourth ventricle. Due to neurologic symptoms, he received radiosurgery (12 Gy in single fraction) soon after diagnosis, with complete neurologic recovery. Then he was treated with 2 cycles of chemotherapy with cisplatin 75 mg/sm IV d1 q21 and pemetrexed 500 mg/sm IV d1 q21 from February to March 2015. Due to lung progression at the first disease evaluation, second-line docetaxel 75 mg/sm IV d1 q21 was prescribed, but it had to be immediately interrupted because of an infusion reaction with rash and hypotension during the administration of the first cycle. Therefore, the treatment was changed to gemcitabine 1250 mg/sm IV d1,8 q21, but after only 2 cycles further lung and liver progression was documented at computed tomography (CT) scan. Moreover, the patient showed a progressive worsening of Performance Status (PS) with dyspnea at rest, cough, severe pain, significant weight loss, and fatigue (Karnofsky PS 50%). In June 2015, as soon as immunotherapy became available at our center, third-line nivolumab 3 mg/kg IV d1 q14 was prescribed, in spite of worsening of the patient's general condition. A significant partial response at all extraencephalic disease sites and brain stability were reported at the first evaluation. Lung and mediastinal lesions underwent further progressive response during the following year, while liver metastases disappeared and the brain lesion remained stable ( Figure 1 ).
In parallel with radiologic response, the patient's condition showed extraordinary gradual improvement with complete recovery of Karnofsky PS to 100%, in a picture of so-called Lazarus syndrome (Table 1) . From June 2016 to November 2017, repeated CT and brain magnetic resonance imaging (MRI) scans confirmed disease stability. No AEs related to immunotherapy were reported until May 2017, when the patient first noticed partial alopecia at hair and eyelashes. In the following month, alopecia rapidly progressed and became complete, involving all body hair, eyelashes, eyebrows, beard, and whiskers ( Figure 2 ). The only concomitant symptom was a mild pruritus without rash, lasting for about 1 month and then spontaneously resolving. After the disappearance of pruritus, onycholysis with Beau lines and nail pitting appeared ( Figure 2 ).
Blood tests to rule out endocrine disorders (e.g. pituitary, adrenal, and gonadal hormones) and sella turcica MRI were performed, without showing any abnormalities. The patient underwent a dermatologic consultation and was diagnosed with alopecia areata on the basis of physical examination. A diagnostic confirmation was obtained through a skin biopsy of the scalp, showing the typical histologic pattern of immune-mediated alopecia (reduced density of deep hair follicles, aspects of intrafollicular malacia, perifollicular and intrafollicular lympho-monocytic infiltrate with prevalence of CD4+ lymphocytes) ( Figure 3 ).
Steroid therapy with oral prednisone 25 mg QD was suggested, but the patient refused it, having concerns regarding toxicity and possible interference with immunotherapy activity. The patient was prescribed topical steroid therapy for hair (1% hydrocortisone lotion), which was tried for about 2 months without any benefits and then interrupted. At present, the patient is still receiving nivolumab. Complete alopecia persists, but the patient's general condition is still excellent and no new toxicities have been reported.
Discussion
Alopecia areata is a common dermatologic disease, affecting 2%-3% of the general population. Its most common manifestation is a non-itchy, nonscarring hair loss in one or more sharply defined body areas. A rare and particularly invalidating variant of this condition is alopecia universalis, inducing a generalized hair loss extended to the whole body surface. Nail alterations like pitting, dystrophy, and Beau lines (i.e. transverse grooves of the nail plate) are frequently associated with the most severe forms of the disease. About one third of patients with alopecia areata undergo spontaneous partial or complete recovery of hair growth from 6 to 12 months from the first manifestations of the disease; however, almost all affected people develop recurrent alopecia in the next years and the condition tends to become chronic. 4 In the case described, we interpreted the development of a rapidly progressing form of alopecia universalis as an immune-related AE consequent to nivolumab treatment. Despite the absence of specific features able to differentiate the iatrogenic variant of the disease from the idiopathic one, this hypothesis was based on different considerations. First, the age at onset of the alopecia in this patient is not consistent with the typical epidemiology of alopecia areata, which makes its first appearance before age 40 in 80% of cases and before age 20 in 50% of cases. Second, the only predisposing factor for idiopathic alopecia areata, in particular for its lateonset forms, is the coexistence of an autoimmune disorder like celiac disease, systemic lupus erythematosus, or Graves hyperthyroidism. 5 Since our patient does not have either familial or personal anamnesis of autoimmunity, no predisposing conditions for alopecia can be identified. Third, alopecia areata has a known autoimmune pathogenesis, which probably involves the activation of T lymphocytes against hair follicles as a consequence of aberrant antigen presentation by particular human leukocyte antigen alleles. 6 Nivolumab, like all ICIs, is able to induce a wide range of immune-mediated AEs potentially affecting all organs and mimicking the corresponding idiopathic conditions. The pathogenesis of immune-mediated toxicity, based on a hyperactivation of T lymphocytes, which lose the physiologic inhibitory stop and react against selfepitopes, is consistent with the underlining mechanism of alopecia areata. 7 However, as neither nivolumab discontinuation after the insurgence of the toxicity nor drug rechallenge were made, the most convincing evidence supporting a correlation between a drug and an AE cannot be obtained. To our knowledge, there is only one previous report in the literature of alopecia areata during immunotherapy for cancer. 8 Notably, all patients had metastatic melanoma or renal cell carcinoma, so this is the first case reported in a patient with NSCLC treated with immunotherapy. Moreover, all the 4 cases described developed skin toxicity in concomitance with other systemic adverse events (colitis, transaminitis, itchy rash and elevated hemoglobin, diabetes mellitus). On the contrary, our patient shows an optimal tolerance to nivolumab and alopecia areata remains the only reported AE. Another aspect to underline in our case is the very late timing of insurgence of the skin toxicity, which occurred after almost 2 years of treatment in a state of absolute well-being, while all previously reported cases of alopecia appeared within the first year from the beginning of immunotherapy. In our patient, the delayed toxicity was associated with an early and prolonged response to treatment, with an exceptional clinical benefit.
Conclusion
This uncommon case underlines the possibility that a wide range of rare toxicities may develop during therapy with ICIs, with atypical features in relation to timing of insurgence, target organs, or both. Although alopecia in the course of immunotherapy is very rare, it can be associated with a radical modification of external appearance, with potentially severe psychological distress. Therefore, concise information about the chance of this uncommon event in the informed consent may be advisable. Furthermore, the essential diagnostic management of ICI-related alopecia should be standardized, in order to exclude potential underlying etiologies. This overview should include endocrine profile of thyroid, gonadal, and adrenal function, and brain MRI with focus on pituitary gland. On the other hand, the possibility that rare and/or severe toxicities may be associated with the efficacy of treatment remains an open issue and deserves further investigation. 9, 10 Comprehension of the pathogenesis of immune-related AEs and the standardization of their management should be optimized in the future, also in the perspective of the emergence of newer therapeutic strategies whose safety profiles may be partially unknown (e.g. anti-LAG, anti-TIM3, anti-GITR).
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